EUVIMEDEUVIMED entdecken
Crossref

Development and Validation of a Novel High-Performance Liquid Chromatography Assay with Ultraviolet Detection for Determination of Asciminib in Human Plasma

Masatomo Miura iD, Naoto Takahashi iD

Journal of Chromatographic Science · 2025

DOI: 10.1093/chromsci/bmaf056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chromatographic Science, 2025. Verfasst von Masatomo Miura und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. Hauptthemen laut MEDLINE: Chromatography, High Pressure Liquid, Pyrazoles, Niacinamide. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A rapid, simple and highly sensitive stability-indicating high-performance liquid chromatography (HPLC) method was developed and validated for the estimation of asciminib in human plasma. Plasma samples (100 μL) were processed by solid-phase extraction. Chromatographic separation was performed using a CAPCELL PAK C18 MGII column (4.6 × 250 mm, 5 μm); the mobile phase consisted of 0.5% potassium dihydrogen phosphate (KH2PO4, pH 3.5): acetonitrile: methanol (50:45:5, v/v/v) at a flow rate of 0.5 mL/min. Detection was carried out at a wavelength of 250 nm. The developed method showed good linearity over the concentration range of 10–5000 ng/mL (correlation coefficient: 0.9999). The method was then validated according to guidelines published by the US Food and Drug Administration. The coefficients of variation for intra- and interday assays for asciminib were less than 13.9%, whereas accuracies for intra- and interday assays were within 8.9%. The limit of quantification was 10 ng/mL. The mean (minimum – maximum) plasma trough concentration of asciminib in 29 Japanese patients with chronic myeloid leukemia who received repeated administration of 40 mg twice daily was 367 (101–807) ng/mL. The validated method can be used as a routine method to support pharmacokinetic studies of asciminib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chromatography, High Pressure LiquidPyrazolesNiacinamideHumansDrug StabilityLimit of DetectionLinear ModelsReproducibility of ResultsSpectrophotometry, Ultraviolet

Substanzen

asciminibPyrazolesNiacinamide

Autor:innen und Institutionen

  • Department of Pharmacokinetics, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
  • Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.

ORCID-Profile: Masatomo Miura, Naoto Takahashi

Zitieren

APA

Miura, M., & Takahashi, N. (2025). Development and Validation of a Novel High-Performance Liquid Chromatography Assay with Ultraviolet Detection for Determination of Asciminib in Human Plasma. Journal of Chromatographic Science. https://doi.org/10.1093/chromsci/bmaf056

Vancouver

Miura M, Takahashi N. Development and Validation of a Novel High-Performance Liquid Chromatography Assay with Ultraviolet Detection for Determination of Asciminib in Human Plasma. Journal of Chromatographic Science. 2025. doi:10.1093/chromsci/bmaf056

BibTeX
@article{Miura2025,
  author = {Miura, Masatomo and Takahashi, Naoto},
  title = {Development and Validation of a Novel High-Performance Liquid Chromatography Assay with Ultraviolet Detection for Determination of Asciminib in Human Plasma},
  journal = {Journal of Chromatographic Science},
  year = {2025},
  doi = {10.1093/chromsci/bmaf056}
}
Kostenlos starten →